Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy

医学 化疗 表型 鉴定(生物学) 肺癌 抗体 肿瘤科 癌症研究 免疫学 内科学 遗传学 基因 生物 植物
作者
Masayuki Shirasawa,Tatsuya Yoshida,Kouya Shiraishi,Ayako Takigami,Daisuke Takayanagi,Tatsuya Imabayashi,Yuji Matsumoto,Ken Masuda,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Masaya Yotsukura,Yukihiro Yoshida,Kazuo Nakagawa,Takaaki Tsuchida,Ryuji Hamamoto,Noboru Yamamoto,Noriko Motoi,Takashi Kohno
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:179: 107183-107183 被引量:28
标识
DOI:10.1016/j.lungcan.2023.107183
摘要

Platinum etoposide plus anti-programmed cell death ligand-1 (PD-L1) antibody therapy is the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, patient characteristics associated with the efficacy of the combination therapy in SCLC are unclear.We retrospectively reviewed post-surgical limited-stage (LS)-SCLC and ES-SCLC patients treated with atezolizumab plus carboplatin and etoposide (ACE). The association between SCLC subtypes based on transcriptomic data and pathological findings, including CD8-positive tumor-infiltrating lymphocyte (TIL) status, was investigated in the LS-SCLC cohort. The association between the efficacy of ACE therapy, pathological subtypes, and TIL status was evaluated in the ES-SCLC cohort.The LS-SCLC cohort (N = 48) was classified into four SCLC subtypes (ASCL1 + NEUROD1 [SCLC-A + N, N = 17], POU2F3 [SCLC-P, N = 15], YAP1 [SCLC-Y, N = 10], and inflamed [SCLC-I, N = 6]) based on transcriptomic data. SCLC-I showed enriched immune-related pathways, the highest immune score (CD8A expression and T-cell-inflamed gene expression profiles), and epithelial-mesenchymal transition (EMT), in transcriptional subtypes. Immunohistochemical staining (IHC) showed that SCLC-I had the highest density of CD8-positive TILs in transcriptional subtypes. In the ES-SCLC cohort, the efficacy of ACE therapy did not differ according to pathological subtypes. The progression-free survival (PFS) of TILHigh patients was significantly longer than that of TILLow patients (PFS: 7.3 months vs. 4.0 months, p < 0.001).Tumors with a high density of TILs, which represent the most immunogenic SCLC subtype (SCLC-I), based on transcriptomic data could benefit from ACE therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被科研通管家采纳,获得10
刚刚
大个的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
所所的应助被科研通管家采纳,获得10
刚刚
Cakoibao的应助被科研通管家采纳,获得10
刚刚
刚刚
Jasper的应助被科研通管家采纳,获得10
刚刚
友好翠安完成签到,获得积分10
刚刚
顾矜的应助被科研通管家采纳,获得10
刚刚
踏实的从蓉完成签到,获得积分10
刚刚
NexusExplorer的应助被科研通管家采纳,获得10
1秒前
小二郎的应助被科研通管家采纳,获得10
1秒前
憨憨完成签到,获得积分10
1秒前
1秒前
张钦奎完成签到,获得积分10
1秒前
科目三的应助被科研通管家采纳,获得10
1秒前
阿木的应助被科研通管家采纳,获得10
1秒前
Cakoibao的应助被科研通管家采纳,获得10
1秒前
1秒前
2秒前
左岸发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
宋文玥完成签到,获得积分10
3秒前
eee完成签到,获得积分10
3秒前
科研通AI6.2的应助被Hase采纳,获得30
3秒前
英俊的铭的应助被平常的化蛹采纳,获得10
3秒前
大模型的应助被旺旺一切顺利采纳,获得10
3秒前
豪哥威威完成签到,获得积分10
3秒前
3秒前
4秒前
wanghua完成签到,获得积分10
4秒前
4秒前
001完成签到,获得积分10
4秒前
科研牛马完成签到,获得积分10
4秒前
4秒前
霁月发布了新的文献求助10
4秒前
彩色的夏之完成签到,获得积分10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185